These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10555931)

  • 1. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside.
    Murry KR; McKinnon PS; Mitrzyk B; Rybak MJ
    Pharmacotherapy; 1999 Nov; 19(11):1252-60. PubMed ID: 10555931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminoglycoside dosages and nephrotoxicity: quantitative relationships.
    Rougier F; Ducher M; Maurin M; Corvaisier S; Claude D; Jelliffe R; Maire P
    Clin Pharmacokinet; 2003; 42(5):493-500. PubMed ID: 12739987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.
    Rybak MJ; Abate BJ; Kang SL; Ruffing MJ; Lerner SA; Drusano GL
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1549-55. PubMed ID: 10390201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-interval aminoglycoside administration for children: a meta-analysis.
    Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
    Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.
    Boyer A; Gruson D; Bouchet S; Clouzeau B; Hoang-Nam B; Vargas F; Gilles H; Molimard M; Rogues AM; Moore N
    Drug Saf; 2013 Apr; 36(4):217-30. PubMed ID: 23508544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy.
    Leehey DJ; Braun BI; Tholl DA; Chung LS; Gross CA; Roback JA; Lentino JR
    J Am Soc Nephrol; 1993 Jul; 4(1):81-90. PubMed ID: 8400072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.
    Finch NA; Zasowski EJ; Murray KP; Mynatt RP; Zhao JJ; Yost R; Pogue JM; Rybak MJ
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.
    Nicolau DP; Freeman CD; Belliveau PP; Nightingale CH; Ross JW; Quintiliani R
    Antimicrob Agents Chemother; 1995 Mar; 39(3):650-5. PubMed ID: 7793867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy.
    Cimino MA; Rotstein C; Slaughter RL; Emrich LJ
    Am J Med; 1987 Dec; 83(6):1091-7. PubMed ID: 3503577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once daily aminoglycoside dosing: maintained efficacy with reduced nephrotoxicity?
    Zhanel GG; Ariano RE
    Ren Fail; 1992; 14(1):1-9. PubMed ID: 1561384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminoglycosides use in patients over 75 years old.
    Fraisse T; Gras Aygon C; Paccalin M; Vitrat V; De Wazieres B; Baudoux V; Lechiche C; Vicens A; Sotto A; Pagani L; Gaillat J; Forestier E; Gavazzi G
    Age Ageing; 2014 Sep; 43(5):676-81. PubMed ID: 24590569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy.
    Pauly DJ; Musa DM; Lestico MR; Lindstrom MJ; Hetsko CM
    Pharmacotherapy; 1990; 10(6):378-82. PubMed ID: 2287556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients.
    Koo J; Tight R; Rajkumar V; Hawa Z
    Am J Med; 1996 Aug; 101(2):177-83. PubMed ID: 8757358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Daily single-dose aminoglycoside administration. Therapeutic and economic benefits].
    Knudsen LM; Frimodt-Møller N; Hansen MT; Hippe E
    Ugeskr Laeger; 1993 May; 155(19):1436-41. PubMed ID: 8316969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.
    Bland CM; Pai MP; Lodise TP
    Pharmacotherapy; 2018 Dec; 38(12):1229-1238. PubMed ID: 30403305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aminoglycoside nephrotoxicity: modeling, simulation, and control.
    Rougier F; Claude D; Maurin M; Sedoglavic A; Ducher M; Corvaisier S; Jelliffe R; Maire P
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1010-6. PubMed ID: 12604535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?
    Barclay ML; Kirkpatrick CM; Begg EJ
    Clin Pharmacokinet; 1999 Feb; 36(2):89-98. PubMed ID: 10092956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-interval aminoglycoside dosing for treatment of enterococcal and staphylococcal osteomyelitis.
    Graham AC; Mercier RC; Achusim LE; Pai MP
    Ann Pharmacother; 2004 Jun; 38(6):936-41. PubMed ID: 15084688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis.
    Hatala R; Dinh T; Cook DJ
    Ann Intern Med; 1996 Apr; 124(8):717-25. PubMed ID: 8633831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.